238 related articles for article (PubMed ID: 34455227)
1. Efficacy and safety of PARP inhibitors in patients with BRCA-mutated advanced breast cancer: A meta-analysis and systematic review.
Sun X; Wang X; Zhang J; Zhao Z; Feng X; Liu L; Ma Z
Breast; 2021 Dec; 60():26-34. PubMed ID: 34455227
[TBL] [Abstract][Full Text] [Related]
2. PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer.
Taylor AM; Chan DLH; Tio M; Patil SM; Traina TA; Robson ME; Khasraw M
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011395. PubMed ID: 33886122
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in
Wang J; Zhang Y; Yuan L; Ren L; Zhang Y; Qi X
Aging (Albany NY); 2020 Nov; 13(1):450-459. PubMed ID: 33257598
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of poly (ADP-ribose) polymerase inhibitors therapy for
Zhang M; Yu X; Wang J; Li Y; Cao L
J Cancer Res Ther; 2021 Dec; 17(7):1672-1678. PubMed ID: 35381738
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis.
Yang Y; Du N; Xie L; Jiang J; Mo J; Hong J; Mao D; Ng DM; Shi H
World J Surg Oncol; 2020 Jul; 18(1):151. PubMed ID: 32622363
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials.
Shao F; Liu J; Duan Y; Li L; Liu L; Zhang C; He S
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32096544
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of PARP inhibitors in the treatment of BRCA-mutated breast cancer: an updated systematic review and meta-analysis of randomized controlled trials.
Sun X; Xu S; Li Y; Lv X; Wei M; He M
Expert Rev Clin Pharmacol; 2023 Mar; 16(3):245-256. PubMed ID: 36908219
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis.
Bao Z; Cao C; Geng X; Tian B; Wu Y; Zhang C; Chen Z; Li W; Shen H; Ying S
Oncotarget; 2016 Feb; 7(7):7629-39. PubMed ID: 26399274
[TBL] [Abstract][Full Text] [Related]
9. PARP inhibitor treatment of advanced breast cancer beyond the
Yan F; Jiang Q; He M; Shen P
Future Oncol; 2021 Jun; 17(18):2381-2393. PubMed ID: 33784822
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of PARP Inhibitors in Advanced or Metastatic Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis.
Liu X; Wu K; Zheng D; Luo C; Fan Y; Zhong X; Zheng H
Front Oncol; 2021; 11():742139. PubMed ID: 34778059
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study.
Kotani H; Masuda N; Yamashita T; Naito Y; Taira T; Inoue K; Takahashi M; Yonemori K; Toyoizumi S; Mori Y; Nagasawa T; Hori N; Iwata H
Breast Cancer; 2022 Nov; 29(6):1088-1098. PubMed ID: 35907135
[TBL] [Abstract][Full Text] [Related]
12. Single-agent PARP inhibitors for the treatment of patients with
Poggio F; Bruzzone M; Ceppi M; Conte B; Martel S; Maurer C; Tagliamento M; Viglietti G; Del Mastro L; de Azambuja E; Lambertini M
ESMO Open; 2018; 3(4):e000361. PubMed ID: 29942664
[TBL] [Abstract][Full Text] [Related]
13. Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis.
Gulia S; Kannan S; Ghosh J; Rath S; Maheshwari A; Gupta S
ESMO Open; 2022 Oct; 7(5):100558. PubMed ID: 36007449
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials.
Hao J; Liu Y; Zhang T; He J; Zhao H; An R; Xue Y
Crit Rev Oncol Hematol; 2021 Jan; 157():103145. PubMed ID: 33254040
[TBL] [Abstract][Full Text] [Related]
15. Poly (ADP-ribose) Polymerase Inhibitors in Patients with Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials.
Chao Z; Wang Z; Li L; Jiang Y; Tang Y; Wang Y; Hao X; Zhang C; Guo X; Yu W; Cheng F; Wang Z
Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138301
[No Abstract] [Full Text] [Related]
16. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Diéras V; Han HS; Kaufman B; Wildiers H; Friedlander M; Ayoub JP; Puhalla SL; Bondarenko I; Campone M; Jakobsen EH; Jalving M; Oprean C; Palácová M; Park YH; Shparyk Y; Yañez E; Khandelwal N; Kundu MG; Dudley M; Ratajczak CK; Maag D; Arun BK
Lancet Oncol; 2020 Oct; 21(10):1269-1282. PubMed ID: 32861273
[TBL] [Abstract][Full Text] [Related]
17. Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis.
Cheng H; Yang J; Liu H; Xiang Y
Arch Gynecol Obstet; 2021 Aug; 304(2):285-296. PubMed ID: 34021367
[TBL] [Abstract][Full Text] [Related]
18. Medical Management of newly diagnosed breast cancer in a BRCA1/2 mutation carrier.
Desai NV; Tung NM
Breast J; 2020 Aug; 26(8):1506-1512. PubMed ID: 32633033
[TBL] [Abstract][Full Text] [Related]
19. PARP Inhibitors for the Treatment of BRCA1/2-Mutated Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
Kunwor R; Silver DP; Abu-Khalaf M
Hematol Oncol Stem Cell Ther; 2023 Apr; 16(3):186-196. PubMed ID: 37023220
[TBL] [Abstract][Full Text] [Related]
20. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Wiggans AJ; Cass GK; Bryant A; Lawrie TA; Morrison J
Cochrane Database Syst Rev; 2015 May; 2015(5):CD007929. PubMed ID: 25991068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]